- Details
- In this 2021 LUGPA presentation, Noah Hahn presents " Biomarkers and Next-Generation Sequencing in Advanced Bladder Cancer Patients" . Dr. Hahn discusses the differences in prognostic biomarkers and predictive biomarkers before discussing PD-L1 on the immunohistochemistry side, sequencing biomarkers, tumor mutational burden, and microsatellite instability or mismatch repair deficient tumors. Biogr...
|
- Details
- In this conversation with Alicia Morgans, Matthew Galsky highlights an exploratory analysis within the IMvigor130 randomized phase III study of patients with metastatic urothelial cancer who were treatment-naive. IMvigor130 was asking two separate questions, should we combine platinum-based chemotherapy with atezolizumab versus giving platinum-based chemotherapy alone, and should we give immune ch...
|
- Details
- In this UroToday discussion between Petros Grivas, MD, PhD, Guru Sonpavde, MD, and Maria Carlo, MD, the trio discuss recent publications on germline testing and genetic profiling. The conversation kicks off with a background on Dr. Carlo’s recent work concerning genetic testing for urothelial and bladder cancer patients. The conversation shifts to hear from Dr. Sonpavde about his recent work in lo...
|
- Details
- In this UroToday GU Oncology Journal Club, Christopher Wallis and Zachary Klaassen highlight a Journal of Clinical Oncology publication on a phase two open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma, progressing after platinum-based chemotherapy and checkpoint inhibitors. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With M...
|
- Details
- In this UroToday discussion between Alicia Morgans and Samuel Funt, they discuss Samuel Funt’s recent phase 2 trial evaluating the use of atezolizumab, with gemcitabine and cisplatin, as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). The conversation begins with background on the study, beginning with Dr. Funt’s description of neoadjuvant cisplatin-based chemotherapy as the standar...
|
- Details
- In this discussion, Alicia Morgans and Terence Friedlander discuss updates from the EV-103 study. The EV-103 study is a phase one/two clinical trial that looked at the combination of enfortumab vedotin and pembrolizumab in, previously treated, patients with cisplatin-ineligible, metastatic urothelial cancer. Historically, cisplatin-ineligible metastatic urothelial cancer patients have had a very p...
|
- Details
- Sean Sachdev and Praneet Polineni delve into their paper on trimodality therapy for muscle-invasive bladder cancer. Dr. Sachdev highlights the growing evidence supporting trimodality therapy as a viable option, especially for older patients who may not be good candidates for surgical intervention. Dr. Polineni offers details on their study, which involved 32 patients with a mean age of 73. The tre...
|
- Details
- Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Unfortunately, up to 50% of these patients are medically ineligible for cisplatin due to low-performance status, renal dysfunction, or other medical comorbidities. Immune checkpoint blockade is a first-line therapeutic option in either platinum ineligible patients or carboplatin eligible pat...
|
- Details
- Several Phase III trials have read out in the first-line treatment of metastatic urothelial cancer in the past few years. In a discussion with Ashish Kamat, Matthew Galsky discusses the expanse in clinical data in metastatic urothelial cancer shaping the treatment landscape. Guiding this conversation, Matthew Galsky focuses on 4 main take-home points and shares optimism in potential development to...
|
- Details
- Alicia Morgans hosts a discussion with Neeraj Agarwal and Petros Grivas about the FDA's approval of sacituzumab govitecan for treating metastatic urothelial carcinoma. Dr. Grivas elaborates on the TROPHY-U-01 trial that led to the drug's approval, emphasizing its efficacy in a heavily pretreated patient population with poor prognostic factors. He notes an overall response rate of 27% and manageabl...
|
